April 26, 2017
Former Retrophin Inc. CEO Martin Shkreli accused his former company of accessing a password-protected trove of his documents and delivering them to investigators seeking to convict him of securities and wire fraud Wednesday, but a prosecutor said the allegation came out of thin air.
April 07, 2017
Attorneys for former Turing Pharmaceuticals Inc. boss Martin Shkreli and his onetime Katten Muchin Rosenman LLP lawyer on Friday urged a Brooklyn federal judge to order separate trials in their securities fraud case, saying their defenses are directly opposed to each other.
March 28, 2017
A former Katten Muchin Rosenman LLP attorney pushed a New York federal court Monday to strike a portion of the securities fraud indictment against him and onetime client ex-pharmaceutical head Martin Shkreli, saying prosecutors used careless language that ropes him into alleged schemes solely charged against Shkreli.
March 07, 2017
Federal prosecutors on Monday urged a New York federal judge not to sever the criminal securities fraud cases of former Turing Pharmaceuticals Inc. CEO Martin Shkreli and his onetime attorney at Katten Muchin Rosenman LLP, saying there is little chance their defense positions at an upcoming trial will be "diametrically opposed."
February 21, 2017
Former Turing Pharmaceuticals Inc. CEO Martin Shkreli and his former Katten Muchin Rosenman LLP attorney have filed motions to sever their criminal securities fraud cases, saying their defenses will be at odds as Shkreli claims he relied on counsel while the attorney says he was kept in the dark.
January 26, 2017
Attorneys for former Turing Pharmaceuticals Inc. CEO Martin Shkreli and his former lawyer at Katten Muchin Rosenman LLP on Thursday told a New York federal judge they intend to move forward with separate bids to sever their criminal securities fraud cases.
January 02, 2017
Court watchers in New York and elsewhere will enter the new year with plenty of Empire State action to keep an eye on, from key Second Circuit decisions on class actions and out-of-court restructurings, to high-profile trials of former Dewey & LeBoeuf LLP executives and notorious pharma entrepreneur Martin Shkreli — the state's reputation as a business-litigation hot spot isn’t going away anytime soon. Here’s a rundown of some of the biggest New York cases practitioners will be paying close attention to in 2017.
January 02, 2017
Trial watchers will have plenty to choose from heading into 2017, including a reprise of the Dewey & LeBoeuf LLP drama, a criminal fraud trial against former Turing Pharmaceuticals CEO Martin Shkreli, and a continuing stream of trials over General Motors' allegedly defective ignition switches.
December 19, 2016
A New York federal judge has ruled the government doesn't have to provide additional detail about its case against a former Katten Muchin Rosenman LLP attorney charged with securities fraud alongside ex-pharmaceutical head Martin Shkreli, finding in part that Shkreli may intimidate any identified co-conspirators.
November 22, 2016
An attorney for former Turing Pharmaceuticals Inc. CEO Martin Shkreli on Tuesday told a Brooklyn federal judge that drugmaker Retrophin Inc. is preventing a swath of documents held by his former lawyers at Katten Muchin Rosenman LLP from coming into Shkreli's criminal case in order to save itself millions of dollars owed to its former CEO.